Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))

B. G.M. Hughes; E. Munoz-Couselo; L. Mortier; Bratland; R. Gutzmer; O. Roshdy; R. González Mendoza; J. Schachter; A. Arance; F. Grange; N. Meyer; A. Joshi; S. Billan; P. Zhang; B. Gumuscu; R. F. Swaby; J. J. Grob

doi:10.1016/j.annonc.2022.05.517

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))

B. G.M. Hughes^*, E. Munoz-Couselo, L. Mortier, Bratland, R. Gutzmer, O. Roshdy, R. González Mendoza, J. Schachter, A. Arance, F. Grange, N. Meyer, A. Joshi, S. Billan, P. Zhang, B. Gumuscu, R. F. Swaby, J. J. Grob

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that a supplementary file for the protocol of the study was mistakenly missed at the time the article was published, although it was cited. The protocol has now been added to the supplementary files. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	853
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	8
DOIs	https://doi.org/10.1016/j.annonc.2022.05.517
State	Published - Aug 2022
Externally published	Yes

Access to Document

10.1016/j.annonc.2022.05.517

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))'. Together they form a unique fingerprint.

Cite this

Hughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F., & Grob, J. J. (2022). Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology, 33(8), 853. https://doi.org/10.1016/j.annonc.2022.05.517

Hughes, B. G.M. ; Munoz-Couselo, E. ; Mortier, L. et al. / Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study) : an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). In: Annals of Oncology. 2022 ; Vol. 33, No. 8. pp. 853.

@article{59f4e0ae64354a3d9d0042831bee9af4,

title = "Corrigendum to {\textquoteleft}Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))",

abstract = "The authors regret that a supplementary file for the protocol of the study was mistakenly missed at the time the article was published, although it was cited. The protocol has now been added to the supplementary files. The authors would like to apologise for any inconvenience caused.",

author = "Hughes, {B. G.M.} and E. Munoz-Couselo and L. Mortier and Bratland and R. Gutzmer and O. Roshdy and {Gonz{\'a}lez Mendoza}, R. and J. Schachter and A. Arance and F. Grange and N. Meyer and A. Joshi and S. Billan and P. Zhang and B. Gumuscu and Swaby, {R. F.} and Grob, {J. J.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = aug,

doi = "10.1016/j.annonc.2022.05.517",

language = "אנגלית",

volume = "33",

pages = "853",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "8",

}

Hughes, BGM, Munoz-Couselo, E, Mortier, L, Bratland, Gutzmer, R, Roshdy, O, González Mendoza, R, Schachter, J, Arance, A, Grange, F, Meyer, N, Joshi, A, Billan, S, Zhang, P, Gumuscu, B, Swaby, RF & Grob, JJ 2022, 'Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))', Annals of Oncology, vol. 33, no. 8, pp. 853. https://doi.org/10.1016/j.annonc.2022.05.517

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study) : an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). / Hughes, B. G.M.; Munoz-Couselo, E.; Mortier, L. et al.

In: Annals of Oncology, Vol. 33, No. 8, 08.2022, p. 853.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study)

T2 - an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))

AU - Hughes, B. G.M.

AU - Munoz-Couselo, E.

AU - Mortier, L.

AU - Bratland,

AU - Gutzmer, R.

AU - Roshdy, O.

AU - González Mendoza, R.

AU - Schachter, J.

AU - Arance, A.

AU - Grange, F.

AU - Meyer, N.

AU - Joshi, A.

AU - Billan, S.

AU - Zhang, P.

AU - Gumuscu, B.

AU - Swaby, R. F.

AU - Grob, J. J.

PY - 2022/8

Y1 - 2022/8

N2 - The authors regret that a supplementary file for the protocol of the study was mistakenly missed at the time the article was published, although it was cited. The protocol has now been added to the supplementary files. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that a supplementary file for the protocol of the study was mistakenly missed at the time the article was published, although it was cited. The protocol has now been added to the supplementary files. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85131802086&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.05.517

DO - 10.1016/j.annonc.2022.05.517

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 35690517

AN - SCOPUS:85131802086

SN - 0923-7534

VL - 33

SP - 853

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Hughes BGM, Munoz-Couselo E, Mortier L, Bratland, Gutzmer R, Roshdy O et al. Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology. 2022 Aug;33(8):853. doi: 10.1016/j.annonc.2022.05.517

Abstract

Access to Document

Other files and links

Fingerprint

Cite this